ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

I last covered ImmunityBio (NASDAQ: IBRX ) in October, a few hours before news came out that it resubmitted its BLA for its lead molecule Anktiva for BCG-unresponsive NMIBC (non-muscle invasive bladder cancer) CIS (carcinoma in situ). My timing wasn't right. IBRX is down 21% from an About the TPT service ing Balance (millio Projected American Shared Revenue Backlog $250 $213 $200 $150 $106 $104 $101 $100 $50 $0 12/31/21 12/31/22 12/31/23 5/10/24 (projected*) Ending Balance Date *This chart includes projecte ...